Eli Lilly and Company (NYSE:LLY) is included among the 12 Best Stocks to Buy for the Long Term. According to a report by ...
U.S. drugmaker Eli Lilly and Company signed an agreement worth up to $1.12 billion with Seamless Therapeutics, the ...
The potentially $1 billion alliance centered around a flexible gene editing technology adds to a portfolio of cutting-edge ...
Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offering by penning a pact with gene editing ...
Last year, a ten-month-old baby in the US was the first person in the world to have their rare genetic disease effectively ...
After a patient safety signal and then death, the FDA in October 2025 placed holds on two of the company’s CRISPR programs ...
Researchers developed a topical gene therapy that corrects disease-causing mutations in human skin models using lipid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results